Phenotypic and oncological insights in <scp>ANNA1</scp> autoimmunity: Age stratification and biomarker analysis
Naveen Kumar Paramasivan(Mayo Clinic in Arizona), Divyanshu Dubey(Mayo Clinic), Georgios Mangioris(Mayo Clinic), Sri Raghav Sista(The University of Texas Health Science Center at Houston), Mohamed Masoud(Mayo Clinic), Andrew M. Knight(Mayo Clinic in Arizona), Andrew McKeon(Mayo Clinic), Haidara Kherbek(Mayo Clinic in Arizona), Anza Zahid(Mayo Clinic), Surendra Dasari(Mayo Clinic in Arizona), John R. Mills(Mayo Clinic), Carley Karsten(Mayo Clinic), Sean J Pittock(Mayo Clinic), Αναστασία Ζεκερίδου(Mayo Clinic)
Cited by 4
Related Papers
Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis
|Annals of Neurology|2018|758
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
|Neurology Neuroimmunology & Neuroinflammation|2021|702
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
|New England Journal of Medicine|2021|553
Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy
|JAMA Neurology|2016|550